Inventor · disambiguated record
Yair Reisner
Also filed as: REISNER YAIR
37 granted patents·25 pending applications·757 citations·filing 1993–2024
98Inventor score
Files withYEDA RES & DEV50REISNER YAIR7ARONOVICH ANNA1TEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD1
Top patents by PatentIndex Score
62 records- 0196US8916147B2Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation toleranceREISNER YAIR·Filed 2006·Granted Dec 23, 2014·29 cites·14 claims
- 0295US6544506B2Veto cells effective in preventing graft rejection and devoid of graft versus host potentialYEDA RES & DEV·Filed 2000·Granted Apr 8, 2003·54 cites·92 claims
- 0393US12508307B2Genetically modified anti-third party central memory T cells and use of same in immunotherapyYEDA RES & DEV·Filed 2023·Granted Dec 30, 2025·1 cites·20 claims
- 0493US5806529ABone marrow transplantationYEDA RES & DEV·Filed 1994·Granted Sep 15, 1998·169 cites·32 claims
- 0591US12391916B2Veto cells generated from memory T cellsYEDA RES & DEV·Filed 2023·Granted Aug 19, 2025·1 cites·27 claims
- 0691US11179448B2Genetically modified anti-third party central memory T cells and use of same in immunotherapyYEDA RES & DEV·Filed 2016·Granted Nov 23, 2021·5 cites·15 claims
- 0791US10961504B2Veto cells generated from memory T cellsYEDA RES & DEV·Filed 2017·Granted Mar 30, 2021·6 cites·37 claims
- 0891US10369172B2Combination therapy for a stable and long term engraftmentYEDA RES & DEV·Filed 2012·Granted Aug 6, 2019·12 cites·29 claims
- 0991US5849288AMethod for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cellsYEDA RES & DEV·Filed 1995·Granted Dec 15, 1998·94 cites·20 claims
- 1089US11844827B2Genetically modified anti-third party central memory T cells and use of same in immunotherapyYEDA RES & DEV·Filed 2021·Granted Dec 19, 2023·1 cites·18 claims
- 1189US10933124B2Methods of transplantation and disease treatmentYEDA RES & DEV·Filed 2016·Granted Mar 2, 2021·4 cites·31 claims
- 1289US10751368B2Methods of transplantation and disease treatmentYEDA RES & DEV·Filed 2018·Granted Aug 25, 2020·6 cites·39 claims
- 1389US9421228B2Use of anti third party central memory T cells for anti-leukemia/lymphoma treatmentREISNER YAIR·Filed 2011·Granted Aug 23, 2016·12 cites·19 claims
- 1489US7270810B2Veto cells effective in preventing graft rejection and devoid of graft versus host potentialYEDA RES & DEV·Filed 2000·Granted Sep 18, 2007·28 cites·55 claims
- 1589US5652373AEngraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systemsYEDA RES & DEV·Filed 1993·Granted Jul 29, 1997·70 cites·47 claims
- 1688US9738872B2Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatmentREISNER YAIR·Filed 2009·Granted Aug 22, 2017·12 cites·22 claims
- 1788US5866757AEngraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systemsYEDA RES & DEV·Filed 1996·Granted Feb 2, 1999·62 cites·33 claims
- 1887US5709843AEngraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoietic deficient immune systemsYEDA RES & DEV·Filed 1994·Granted Jan 20, 1998·65 cites·23 claims
- 1986US11773372B2Veto cells generated from memory T cellsYEDA RES & DEV·Filed 2021·Granted Oct 3, 2023·1 cites·21 claims
- 2086US8974779B2Disease treatment via developing non-syngeneic graft transplantationREISNER YAIR·Filed 2005·Granted Mar 10, 2015·15 cites·7 claims
- 2185US10434121B2Combination therapy for a stable and long term engraftment using specific protocols for T/B cell depletionYEDA RES & DEV·Filed 2012·Granted Oct 8, 2019·6 cites·29 claims
- 2283US7780993B2Therapeutic transplantation using developing, human or porcine, renal or hepatic, graftsYEDA RES & DEV·Filed 2005·Granted Aug 24, 2010·8 cites·30 claims
- 2381US11324777B2Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatmentYEDA RES & DEV·Filed 2017·Granted May 10, 2022·1 cites·18 claims
- 2481US9833482B2Mammalian fetal pulmonary cells and therapeutic use of sameYEDA RES & DEV·Filed 2012·Granted Dec 5, 2017·9 cites·24 claims
- 2579US2023039904A1Combination therapy for a stable and long term engraftmentYEDA RES & DEV·Filed 2022·Application pending·0 cites
- 2677US11555178B2Genetically modified veto cells and use of same in immunotherapyYEDA RES & DEV·Filed 2018·Granted Jan 17, 2023·2 cites·26 claims
- 2776US11504399B2Combination therapy for a stable and long term engraftment using specific protocols for T/B cell depletionYEDA RES & DEV·Filed 2019·Granted Nov 22, 2022·0 cites·24 claims
- 2876US11497776B2Combination therapy for a stable and long term engraftmentYEDA RES & DEV·Filed 2019·Granted Nov 15, 2022·0 cites·22 claims
- 2975US12133866B2Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatmentYEDA RES & DEV·Filed 2022·Granted Nov 5, 2024·0 cites·19 claims
- 3070US5849987AAnimal model for hepatitis virus infectionYEDA RES & DEV·Filed 1994·Granted Dec 15, 1998·27 cites·12 claims
- 3169US5858328AAnimal model for hepatitis virus infectionYEDA RES & DEV·Filed 1994·Granted Jan 12, 1999·26 cites·12 claims
- 3269US2023256028A1Methods of using pulmonary cells for transplantation and induction of toleranceYEDA RES & DEV·Filed 2023·Application pending·0 cites
- 3367US2007264274A1Veto cells effective in preventing graft rejection and devoid of graft versus host potentialYEDA RES & DEV·Filed 2007·Application pending·0 cites
- 3466US2015104471A1Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation toleranceYEDA RES & DEV·Filed 2014·Application pending·0 cites
- 3565US5804160AAnimal model for hepatitis virus infectionYEDA RES & DEV·Filed 1997·Granted Sep 8, 1998·15 cites·5 claims
- 3664US2024325456A1Multipotent lung progenitor cells for lung regenerationYEDA RES & DEV·Filed 2024·Application pending·0 cites
- 3761US2022265726A1Use of veto cells for the treatment of sickle cell diseaseYEDA RES & DEV·Filed 2022·Application pending·0 cites
- 3861US2022265725A1Use of veto cells in treatment of t cell mediated autoimmune diseasesYEDA RES & DEV·Filed 2022·Application pending·0 cites
- 3960US9610331B2Methods for hematopoietic precursor mobilizationARONOVICH ANNA·Filed 2010·Granted Apr 4, 2017·1 cites·11 claims
- 4059US2005232904A1Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological toleranceYEDA RES & DEV·Filed 2005·Application pending·0 cites
- 4154US2020289582A1Conditioning protocols and use of same for tissue regenerationYEDA RES & DEV·Filed 2020·Application pending·0 cites
- 4254US2003147859A1Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological toleranceFiled 2001·Application pending·0 cites
- 4354US2023321235A1Veto car-t cellsYEDA RES & DEV·Filed 2021·Application pending·0 cites
- 4453US2011236405A1Coagulation factor modulation for controlling transplant organ sizeTEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD·Filed 2009·Application pending·0 cites
- 4552US6254867B1Human monoclonal antibodies to the hepatitis B surface antigenYEDA RES & DEV·Filed 1997·Granted Jul 3, 2001·12 cites·12 claims
- 4651US10668109B2Conditioning protocols and use of same for tissue regenerationYEDA RES & DEV·Filed 2016·Granted Jun 2, 2020·0 cites·13 claims
- 4751US2004136972A1Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissuesYEDA RES & DEV·Filed 2004·Application pending·0 cites
- 4851US2023398214A1Anti-viral central memory cd8+ veto cells in haploidentical stem cell transplantationYEDA RES & DEV·Filed 2020·Application pending·0 cites
- 4951US2004082064A1Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissuesYEDA RES & DEV·Filed 2003·Application pending·0 cites
- 5051US2015190546A1Therapeutic transplantation using developing, human or porcine, renal or hepatic, graftsYEDA RES & DEV·Filed 2015·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →